Additionally, EZH2 can promote tumorigenesis, independently of the PRC2 complex, through non-canonical pathways such as the binding of cMyc and p300 to activate AML-related genes (Wang et al., 2022) (Fig. 2). The gene discussed is MYC; the disease is acute myeloid leukemia.